All In Biotech

Drug Trial Radar · NCT05316428

A Study of the Hemodynamic Interactions of TPN171H Tablets & Alcohol in Healthy Male Subjects

A Randomized, Blind, Placebo-controlled, Three-way Crossover Study Evaluating the Interaction of TPN171H Tablets and Alcohol in Healthy Chinese Male Subjects

Last checked: Nov 20, 2026Latest source record: May 23, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

19

Actual

Start

Feb 24, 2022

Primary completion

Apr 2, 2022

Study completion Apr 6, 2022

Sponsor

Lead sponsor
Vigonvita Life SciencesIndustry
Sponsor type
Industry
First posted
Apr 7, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 21 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is primarily to evaluate the effects of taking TPN171H tablets with alcohol on blood pressure, pulse,and pharmacokinetic in Chinese healthy male subjects.

Conditions

  • Alcohol
  • Phosphodiesterase Inhibitor
  • Erectile Dysfunction

Interventions

  • TPN171H tablet plus alcoholDrug

    10 mg TPN171H tablet QD plus 0.5 g/kg alcohol

  • alcoholOther

    0.5 g/kg alcohol

  • TPN171H tabletDrug

    10 mg TPN171H tablet QD

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum change in blood pressure (SBP and DBP)Time frame: 48 hours after treatment
  2. Maximum change in pulseTime frame: 48 hours after treatment
  3. The area under effect-time curve (AUEC0- 4h) of supine systolic (SBP) and diastolic (DBP) blood pressure, and pulseTime frame: 4 hours after treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai Xuhui Central Hospital

    Shanghai, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.